bit.bio CEO Dr Mark Kotter, discusses how he's overseen the development of a unique approach to "reprogram" stem cells with opti-oxTM technology and how bit.bio can change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's, Alzheimer's, and ALS.
Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.